
BillionToOne
BillionToOne is a YC Summer 2017 (S17) company. Based in Menlo Park, CA, USA. Team of 300.
About BillionToOne
Summary
BillionToOne builds single-molecule DNA diagnostics for prenatal screening and oncology. Its proprietary Quantitative Counting Templates technology directly measures sparse disease-causing DNA fragments from a single blood draw, replacing the need for invasive procedures. The Unity Complete prenatal test screens fetal risk for both recessive conditions and chromosomal abnormalities from maternal blood, while the Northstar liquid biopsy tests guide cancer therapy selection and track treatment response in real time.
Business model
Fee per diagnostic test ordered by clinicians or health systems.
Go-to-market
Clinicians and health systems order BillionToOne's tests as laboratory services, with the company processing samples in its own CLIA lab and integrating results via EMR connections.
From the Y Combinator listing
The genetic testing platform detecting and measuring disease.
BillionToOne has developed a DNA molecular counter that increases the cell-free DNA diagnostics resolution by over 1,000 fold, which unlocks transformative improvements in prenatal screening and liquid biopsy for cancers. Unity Screen, BillionToOne's commercially available non-invasive prenatal test (NIPT), is the only NIPT that can assess fetal risk for both recessive conditions and aneuploidies from maternal blood. UNITY Screen continues to grow exponentially and is on its path to becoming the next standard-of-care, with an increasing number of publications showing its accuracy and advantages over other screening methods. We have also recently used our molecular counting technology to develop liquid biopsy tests, which have the potential to completely transform oncology care.
Facts
- Healthcare / Healthcare -> Diagnostics
- Menlo Park, CA, USA
- 300
- Public
- Growth
Founders (2)
- David Tsao
- Oguzhan Atay
Score every batch against your own thesis
GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.
How Accelerator intelligence works